APJO COVID-19 FAQs

在現時缺乏安全有效的疫苗和藥物的情況下,強制全民口罩也許是預防和消除COVID-19的最大希望。想知道更多詳情,請瀏覽:

2. Selected Publications: Eye & Non-Eye-Related

In the midst of COVID-19, the scientific study and research into the virus and disease, and the sharing of such findings, is key. Over the past 4 months, over 4,000 scientific articles on the novel coronavirus have been published! In view of this, we have selected 32 important publications in areas of eye-related preventive measures, ocular involvement, clinical characteristic, infectivity and vaccine development of COVID-19 etc. The list is as shown below.

Selected Eye-Related Publications

# Article Category (Date)
1 李雪杰, 汪明, 陈长征, et al. 伴发或首发病毒性结膜炎的新型冠状病毒感染下眼科医师的防控策略. 中华实验眼科杂志. 2020,38.网络预发表

(http://rs.yiigle.com/yufabiao/1181982.htm)

Ocular involvement

(Feb 2020)

2 L Chen, C Deng, X Chen, et al. Ocular manifestations and clinical characteristics of 534 cases of COVID-19 in China: A cross-sectional study. preprint on medRxiv

(https://www.medrxiv.org/content/10.1101/2020.03.12.20034678v1)

Ocular involvement

(Mar 2020)

3 J Xia, J Tong, M Liu, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. Journal of Medical Virology. In press

(https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25725)

Ocular involvement

(Feb 2020)

4 X Sun, X Zhang, X Chen, et al. The infection evidence of SARS-COV-2 in ocular surface: a single-center cross-sectional study. preprint on medRxiv

(https://www.medrxiv.org/content/10.1101/2020.02.26.20027938v1)

Ocular involvement

(Feb 2020)

5 C Deng, Y Yang, H Chen, et al. Ocular Detection of SARS-CoV-2 in 114 Cases of COVID-19 Pneumonia in Wuhan, China: An Observational Study. The Lancet (preprint)

(https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3543587)

Ocular involvement

(Feb 2020)

6 JP Li, DSC Lam, Y Chen, et al. Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear. British Journal of Ophthalmology. 2020;104(3):297-298.

(https://bjo.bmj.com/content/104/3/297)

Ocular involvement

(Feb 2020)

7 W Deng, L Bao, H Gao, et al. Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular 2 conjunctival route. preprint on bioRxiv

(https://www.biorxiv.org/content/10.1101/2020.03.13.990036v1)

Ocular involvement

(Mar 2020)

8 P Wu, F Duan, C Luo, et al. Characteristics of Ocular Findings of Patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmology. In press.

(https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2764083)

Ocular involvement

(Mar 2020)

9 AY Yu, R Tu, X Shao, et al. A comprehensive Chinese experience against SARS-CoV-2 in ophthalmology. Eye and Vision. In press

(https://eandv.biomedcentral.com/articles/10.1186/s40662-020-00187-2#citeas)

Preventive measures

(Apr 2020)

10 李纯纯, 唐媛, 陈张艳, et al. 非接触式眼压计测量产生气溶胶密度变化及其对疫情防护的意义.中华实验眼科杂志, 2020,38:网络预发表.

(http://rs.yiigle.com/yufabiao/1182990.htm?from=groupmessage&isappinstalled=0)

Preventive measures

(NCT – aerosol generation)

(Feb 2020)

11 KH Wan, SS Huang, A Young, et al. Precautionary measures needed for ophthalmologists during pandemic of the coronavirus disease 2019 (COVID‐19). Acta Ophthalmologica. 2020;98(3):221-222.

(https://onlinelibrary.wiley.com/doi/10.1111/aos.14438)

Preventive measures

(Mar 2020)

12 张明昌, 谢华桃, 许康康, et al, 新型冠状病毒疫情期间眼科检查器具的消毒及医务人员的防护. 中华眼科杂志,2020,56(00): E001

(http://rs.yiigle.com/yufabiao/1180123.htm)

Preventive measures

(Feb 2020)

13 THT Lai, EWH Tang, SKY Chau, et al. Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2020;258:1049-1055.

(https://link.springer.com/article/10.1007/s00417-020-04641-8)

Preventive measures

(Mar 2020)

 

14 J Li, J Shantha, TY Wong, et al. Preparedness among Ophthalmologists: During and Beyond the COVID-19 Pandemic. Ophthalmology. 2020;127(5):569-572.

(https://www.aaojournal.org/article/S0161-6420(20)30319-5/fulltext)

Preventive measures

(Mar 2020)

15 P Ruamviboonsuk, T Lai, A Chang, et al. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19. Asia-Pacific Journal of Ophthalmology.2020;9(2):85-87.

(https://journals.lww.com/apjoo/Fulltext/2020/04000/Chloroquine_and_Hydroxychloroquine_Retinal.5.aspx)

Treatment effects on eyes

(Apr 2020)

16 DSC Lam, KHW Lai, RLM Wong, et al. COVID-19: Special Precautions in Ophthalmic Practice and FAQs on Personal Protection and Mask Selection. Asia-Pacific Journal of Ophthalmology. 2020;9(2):67-77.

(https://journals.lww.com/apjoo/Fulltext/2020/04000/COVID_19__Special_Precautions_in_Ophthalmic.3.aspx)

Preventive measures

(Apr 2020)

17 RLM Wong, SS Huang, J Jonas, et al. COVID-19 Pandemic: Ways Forward. Asia-Pacific Journal of Ophthalmology.2020;9(2):59-60.

(https://journals.lww.com/apjoo/Fulltext/2020/04000/COVID_19_Pandemic__Ways_Forward.1.aspx)

Insight

(Apr 2020)

Selected Non-Eye-Related Publications

# Title Category (date)
1 W Guan, Z Ni, Y Hu, et al. Clinical characteristics of coronavirus disease 2019 in china. The New England Journal of Medicine. In press.

(https://www.nejm.org/doi/full/10.1056/NEJMoa2002032)

Clinical characteristics

(PRC cases)

(Feb 2020)

2 JR Lechien, CM Chiesa-Estomba, DR De Siati, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology. In press

(https://link.springer.com/article/10.1007/s00405-020-05965-1)

Clinical characteristics

(Europe cases)

(Apr 2020)

3 R Wölfel, VM Corman, W Guggemos, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. In press

(https://www.nature.com/articles/s41586-020-2196-x)

Virology

(Apr 2020)

4 S Zhao, Q Lin, J Ran et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. International Journal of Infectious Diseases. 2020;92:214-217

(https://www.ijidonline.com/article/S1201-9712(20)30053-9/fulltext)

Infectivity

(Mar 2020)

5 K Sun, J Chen and C Viboud. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. The Lancet Digital Health. 2020;2(4):201-208

(https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30026-1/fulltext)

Infectivity

(Feb 2020)

6 C Rothe, M Schunk, P Sothmann, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. The New England Journal of Medicine. 2020; 382:970-971

(https://www.nejm.org/doi/full/10.1056/NEJMc2001468)

Infectivity

(Asymptomatic transmission)

(Jan 2020)

7 L Bourouiba. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19. JAMA. In press.

(https://jamanetwork.com/journals/jama/article-abstract/2763852)

Droplets travel distance

(Mar 2020)

8 N Doremalen, T Bushmaker, DH Morris et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The New England Journal of Medicine. In press.

(https://www.nejm.org/doi/full/10.1056/NEJMc2004973)

Survival time

(Mar 2020)

9 EK McCreary and JM Pogue. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases. 2020;1(4):ofaa105

(https://academic.oup.com/ofid/article/7/4/ofaa105/5811022)

Treatment

(Mar 2020)

10 Jonathan Grein, Norio Ohmagari, Daniel Shin, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine. New England Journal of Medicine. In press.

(https://www.nejm.org/doi/full/10.1056/NEJMoa2007016)

Treatment

(Remdesivir)

(Apr 2020)

11 L Caly, JDDruce, MG Catton, et al. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020;178:104787.

(https://www.sciencedirect.com/science/article/pii/S0166354220302011)

Treatment

(Ivermectin)

(Apr 2020)

12 J Ren, A Zhang and X Wang. Traditional Chinese medicine for COVID-19 treatment. Pharmacological Research. 2020;155:104743

(https://www.sciencedirect.com/science/article/pii/S1043661820307556?via%3Dihub)

Treatment

(Chinese Medicine)

(Mar 2020)

13 C Liu, Q Zhou, Y Li et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. 2020;6(3):315-331

(https://pubs.acs.org/doi/abs/10.1021/acscentsci.0c00272)

Vaccine

(Mar 2020)

14 N Lurie, M Saville, R Hatchett, et al. Developing Covid-19 Vaccines at Pandemic Speed. The New England Journal of Medicine. In press.

(https://www.nejm.org/doi/full/10.1056/NEJMp2005630)

Vaccine

(Mar 2020)

15 DSW Ting, L Carin, Victor Dzau, et al. Digital technology and COVID-19. Nature Medicine. 2020;26:459-461

(https://www.nature.com/articles/s41591-020-0824-5)

Prevention and mitigation

(Digital technology)

(Mar 2020)